Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Next Previous
Trial Profile

Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isoquercetin (Primary) ; Masitinib (Primary) ; Hydroxychloroquine
  • Indications COVID-19 pneumonia; Lung disorders
  • Focus Therapeutic Use
  • Sponsors AB Science

Most Recent Events

  • 10 Oct 2024 According to an AB Science media release, The study initially planned to recruit 200 patients (over 18 years of age with no upper age limit). Following a DSMB recommendation, decision was taken to continue the study only in level 4 patients (i.e. hospitalized patients with oxygen supply <6 L/min with SpO2 maintained =92%).
  • 08 Jul 2024 According to an AB Science media release, the trial objective was to detect a trending treatment effect with 95 patients that would translate into a significant effect when simulating the same effect with the planned enrolment of 200 patients. If this objective was reached, then the conclusion would be that it is worth continuing to evaluate masitinib as an agent in the treatment of covid in patients hospitalized with moderate need of oxygen.
  • 08 Jul 2024 According to an AB Science media release, company today announces the results of a Phase 2 study evaluating masitinib in COVID-19. The study could not recruit the planned 200 patients. The decision was therefore taken to stop inclusion after 95 patients were randomized.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top